Stay updated with breaking news from Christopher Rajkumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months
(UPDATED) In patients not taking antianginal meds, PCI clearly alleviated some—but not all—symptoms. What does that mean in practice?
Positive six-month clinical data were announced by Elixir Medical during the Transcatheter Cardiovascular Therapeutics (TCT) conference, TCT 2023, in San Francisco, CA today. The DESyne BDS Plus Randomized Controlled Trial (RCT) evaluated DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES).